BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced Thursday that it has entered into an agreement with Eurofins Discovery for pharmacology studies of Eurofins' TD-0148A.
TD-0148A is a second-generation Lysergic Acid Diethylamide (LSD) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations.
The US Food and Drug Administration (FDA) enabled the studies under its Investigational New Drug (IND) designation.
READ: BetterLife Pharma inhaled coronavirus treatment passes six months of cold temperature tests
"Following our recent acquisition of the assets of Transcend Biodynamics, we are excited to be initiating the IND-enabling studies for TD-0148A,” said BetterLife CEO Dr Ahmad Doroudian in a statement. “We look forward to working with Eurofins Discovery to bring this treatment to patients as quickly as possible as we prepare for our IND and trials."
Eurofins will be conducting the IND-enabling in-vitro preclinical primary pharmacology and safety pharmacology studies on TD-0148A at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs.
Dr. Doroudian added: "We are pleased to be partnering with Eurofins Discovery in the global Eurofins Discovery team for the TD-0148A IND-enabling primary and safety pharmacology studies. TD-0148A is a potential novel new therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and post-traumatic stress disorder. BetterLife’s goal is to bring this treatment to IND and the clinic as soon as possible, and Eurofins Discovery, with its expertise and state-of-the-art capabilities, is an ideal partner to help us realize our vision."
Eurofins said partnering with BetterLife to conduct the IND-enabling in vitro studies on TD-0148A complements well with Eurofins’ expertise and utilizes its approach to bringing in several different units in the US and Europe, each with its own specialty.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham